Highly selective HPK1 inhibitor NDI-101150 mediates immune cell activation and robust antitumor responses, distinct from immune checkpoint blockade
David Ciccone(Harvard University), Christine Loh(Ensemble Therapeutics (United States)), Fu‐Shan Kuo(Ensemble Therapeutics (United States)), Scott Boiko(Ensemble Therapeutics (United States)), Peter J. Tummino(Intarcia Therapeutics (United States)), Samantha Carreiro(Ensemble Therapeutics (United States)), Neelu Kaila, Joshua J McElwee(Ensemble Therapeutics (United States))
Cited by 8
Related Papers
Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori
|Nature|1999|1.9k
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
|Nature|2012|1.8k
Hydrolysis of Biological Peptides by Human Angiotensin-converting Enzyme-related Carboxypeptidase
|Journal of Biological Chemistry|2002|1.4k
Residence Time of Receptor−Ligand Complexes and Its Effect on Biological Function
|Biochemistry|2008|550